This page is updated frequently with new Antibodies-related patent applications.
|| List of recent Antibodies-related patents
| Device and blood analysis by image processing|
The present application describes a new device and method of use thereof, which allows identifying certain antigens and antibodies present in the blood. The device of the present invention is a closed device consisting of two parts, wherein the upper part (1) comprises a chamber (3) surrounded by leds (4) illuminating the analysis plate (8), which is supported by the rotating platform (6).
Universidade Do Minho
| Rapid isolation of monoclonal antibodies from animals|
Methods and compositions for identification of candicate antigen-specific variable regions as well as generation of antibodies or antigen-binding fragments that could have desired antigen specificity are provided. For example, in certain aspects methods for determining amino acid sequences of serum antibody cdr and abundancy level are described.
Board Of Regents, The University Of Texas System
| Mammalian protein co-recognition by broadly neutralizing antibodies as modified immunogens for re-elicitation|
The present invention relates to using hiv-1 broadly neutralizing antibodies to screen for glycan-dependent or protein-dependent self reactivities inherent in these mutated antibodies, and defining this cross recognition at the molecular level, and utilizing the information to re-elicit trimer-specific and/or n-glycan-dependent or protein-surface-dependent broadly neutralizing antibodies and therapeutic applications thereof.. .
The Scripps Research Institute
| Methods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof|
Provided herein is a method for selecting and expanding polypeptide epitopes against disease-specific antibodies present in blood across a wide variety of antibody-mediated infectious and autoimmune diseases. In particular, high-throughput selection methods are provided for selecting and expanding disease-relevant polypeptide epitopes against disease-specific antibodies present in a sample from a subject using polypeptide epitope libraries.
The Regents Of The University Of California
| Methods of detecting donor-specific antibodies and systems for practicing the same|
Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (ag) to form an immune antibody-ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-ag complex (e.g., the ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient.
The Board Of Trustees Of The Leland Stanford Junior University
| Use of polyclonal and monoclonal antibodies specific for 3-phosphohistidine|
Isolated monoclonal antibodies and antigen binding fragments are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at n3 (3-phis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed.
Salk Institute For Biological Studies
| Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies|
The present disclosure relates to anti-cd200 antibodies (e.g., variant anti-cd200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient.. .
Alexion Pharmaceuticals, Inc.
| Antibodies for the identification of pancreatic disorders|
Levels of vegf-a, vegf-c and pge2 were measured in patient groups presenting with different types of pancreatic lesions. Pancreatic fluids that exhibited high levels of vegf-a and relative low levels of vegf-c correlated well with a diagnosis of serous cystadenoma.
Indiana University Research And Technology Corp.
| Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens|
Methods of identifying antigen-specific antibody-secreting and antibody-forming cells, such as antigen-specific b cells, and methods for cloning the antigen-specific antibody sequences of the antibody produced by these cells are provided. In particular, the methods include enriching b cells for antigen-specific b cells, culturing the antigen-specific b cells to generate clonal b cell populations, detecting clonal b cells that produce a single antigen-specific antibody, optionally screening the clonal b cell populations for functional activity, staining and sorting the cells to isolate the antigen-specific b cells, sequencing the nucleic acids encoding the antigen-specific antibody sequences, expressing the sequences to produce an antibody, isolating the antibody and screening the antibody for antigen recognition.
Alder Biopharmaceuticals, Inc.
| Haptenes and conjugates derived from pyocyanin, antibodies thereof, and immunichemical detecting infections caused by pseudomonas aeruginosa|
An object of the present invention is also a conjugate of said compound i with a carrier protein or fragment thereof, with a detectable labelling agent, or with a polymer or support, and to the use thereof for producing antibodies. Furthermore, the present invention also relates to a method for the detection and/or quantification of 1-hydroxyphenazine and/or pyocyanin using said antibodies and conjugates for the detection of infections caused by pseudomonas aeruginosa..
Detection and use of antiviral resistance mutations
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies.
Preparations and methods for treating malignancies
Disclosed are therapeutic formulations comprising antibodies against the pekraekiwk (seq id no:1) epitope of the monomeric isoform of a-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed..
Ask Diagnostics, Inc.
Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases
The present disclosure relates to anti-ige antibodies that bind to novel antigenic epitopes of the csmx domain, e.g., svphprchcgagra (seq id no: 4) and the uses thereof in treating ige-mediated diseases.. .
Molecules and methods for treatment of diabetes
Described are antibodies that specifically recognize and bind the epitope of glutamate decarboxylase (gad65) that is bound by antibody b96.11, and anti-idiotypic antibodies that are capable of competing with gad65 for binding with b96.11 and competitively inhibit such binding. These antibodies can be provided in the form of a pharmaceutical composition and can be used in methods for delaying the onset of type 1 diabetes and for inhibiting insulitis and other diabetic symptoms.
University Of Washington
Stabilized formulations containing anti-pcsk9 antibodies
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (pcsk9). The formulations may contain, in addition to an anti-pcsk9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant.
Regeneron Pharmaceuticals, Inc.
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr and having increased ph sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind pcsk9 and have increased ph sensitivity, improved binding affinity and/or increased in vivos half life.
Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
The application discloses a combination of two monospecific tfpi antibodies, wherein one antibody is capable of specifically binding tfpi (1-181) and the other antibody is capable of specifically binding tfpi (182-276), as well as bispecific anti-tfpi antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length tfpiα, even where the concentration of tfpi is abnormally elevated..
Novo Nordisk A/s
Her3 specific monoclonal antibodies for diagnostic and therapeutic use
Isolated or recombinant anti-her3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer..
The Board Of Regents Of The University Of Texas System
High affinity anti-gd2 antibodies
In this application are described high affinity anti-gd2 antibody agents, and various methods and reagents related thereto, including for example for the detection, prevention, and/or therapeutical treatment of gd2-related diseases, in particular, neuroblastoma.. .
Memorial Sloan-kettering Cancer Center
Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg.
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention.
Hybridoma clones and monoclonal antibodies to cd9
The present invention is directed to a monoclonal antibody that recognizes human cd9 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome isolation kits using the antibody..
The Translational Genomics Research Institute
Anti-rankl antibodies and methods of use
The present invention provides anti-rankl monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.. .
Il-11r binding proteins
The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (il-11) receptor alpha (il-11rα) and uses thereof, e.g., in therapy.. .
45 Poplar Road
Antibodies against g-csfr and uses thereof
The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.. .
Methods and compositions relating to anti-ccr7 antigen binding proteins
The present invention provides compositions and methods relating to antigen binding proteins against ccr7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.. .
Anti il-3r alpha agents and uses thereof
The present disclosure provides antibodies and antigen binding fragments thereof that bind to an epitope within an interleukin-3 receptor α.. .
Novel antibodies for the treatment of hiv
More particularly, the present invention relates to the 515h7 and 301ae5 monoclonal antibodies, specific to the cxcr4 protein, as well as their use for the treatment of hiv infection. Pharmaceutical compositions comprising such antibodies and a process for the selection of such antibodies are also covered..
Il3ralpha antibody conjugates and uses thereof
The present invention provides antibodies that bind to the il-3 receptor alpha subunit alpha (il3rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an il3rα-expressing cell population, the methods comprising contacting a population of il3rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to il3rα.
Stemline Therapeutics, Inc.
Compositions and methods for increasing muscle growth
This disclosure is in the field of anti-activin receptor iib (actriib) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse..
Anti-alpha v beta 6 antibodies and uses thereof
Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent αvβ6-mediated diseases such as fibrosis and cancer..
Biogen Ma Inc.
Multivariable antigens complexed with targeting humanized monoclonal antibody
The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.. .
Baylor Research Institute
Therapeutic dll4 binding proteins
Dll4 binding proteins are described herein, including antibodies, cdr-grafted antibodies, humanized antibodies, and dll4 binding fragments thereof, proteins that bind dll4 with high affinity, and dll4 binding proteins that neutralize dll4 and/or vegf activity. The dll4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis..
Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
The disclosure relates to charge-engineered antibodies and penetration-enhanced targeted proteins and their uses for therapeutic treatment or therapeutics delivery.. .
Permeon Biologics, Inc.
Humanized antibodies that bind lgr5
Disclosed herein are humanized anti-lgr5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind lgr5 without disrupting lgr5-rspo1 binding or signaling, and may disrupt lgr5 signaling through wnt that is independent of rspo1.
Methods for treating crohn's disease using an anti-il23 antibody
The invention relates to products and methods for treating crohn's disease. The products relate to antibodies that inhibit native human il-23 while sparing il-12.
Methods and compositions for delivering mrna coded antibodies
The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mrnas encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject. In some embodiments, the one or more mrnas comprise a first mrna encoding the heavy chain and a second mrna encoding the light chain of the antibody..
Shire Human Genetic Therapies, Inc.
Compositions and methods for growth factor modulation
Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the tgf-β superfamily of proteins..
Scholar Rock, Inc.
Methods and compositions for the generation and use of conformation-specific antibodies
The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof.. .
Beth Israel Deaconess Medical Center, Inc.
The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration..
Prothena Biosciences Limited
Compositions and methods for antibodies targeting complement protein c5
The present invention relates to antibodies targeting complement protein c5 and compositions and methods of use thereof.. .
Methods and compositions useful in manipulating the stability of re1 silencing transcription factor
Disclosed are methods of screening for compounds that promote rest degradation by inhibiting the activity of the cdtsp1 phosphorylase including fluorescent and antibody based screens. Also disclosed are peptides that promote rest stabilization as well as antibodies that recognize rest phosphorylated at serine 861 and serine 864..
Oregon Health & Science University
Anti-gcc antibody molecules and related compositions and methods
antibodies and antigen-binding fragments of antibodies that bind gcc are disclosed. In some embodiments, the antibodies are humanized, chimeric or human.
Thomas Jefferson University
Antibody drug conjugates
The present invention relates to anti-ckit antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. .
Antibody-nanoparticle conjugates for the treatment of drug abuse
The present invention generally relates to an antibody composition including antibodies conjugated to nanoparticles. The antibody composition may be used in methods to treat drug use, drug addiction, and effects of drug use..
Board Of Trustees Of The University Of Arkansas
Polyoxazoline antibody drug conjugates
In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer adcs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (dar) of the antibody significantly beyond the currently available technology.
Serina Therapeutics, Inc.
Immunogenic composition in emulsion form
To its preparation method and its uses, notably for producing antibodies, as a drug or in an immunization method.. .
Formulation of human antibodies for treating tnf-alpha associated disorders
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. .
Abbvie Biotechnology Ltd
Methods to enhance cancer treatment
Herein are provided methods for reducing or eliminating cancer in a patient in need of cancer treatment, by providing cholesterol deprivation therapy (cdt) in conjunction with antibodies directed against cholesterol-deprived tumor cells. Further provided are methods of enhancing the efficacy of other cancer treatments, by administering cdt and antibodies directed against cholesterol-deprived tumor cells, in combination with additional anti-cancer therapies..
International Business Machines Corporation
Compositions and methods of treating fungal and bacterial pathogens
The invention features isolated polypeptides and conjugates including the amino acid sequence of any one of seq id nos: 3-11, or a variant sequence thereof having up to three substitutions, deletions, or additions to the amino acid sequence of any one of seq id nos: 3-11, wherein the polypeptide does not include more than 20 contiguous amino acids of seq id no: 2 or seq id no: 17. Additional polypeptides includes those of formula (i) [znzpvssbsfsyt]n and formula (ii) [znuwoobufoyt]n.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
Targeted elimination of factor viii immune cells
This disclosure relates to composition and methods for improving blood clotting in a subject that developed anti-factor viii antibodies. In certain embodiments, this disclosure contemplates a conjugate comprising a toxin, e.g., ricin, abrin, saporin, coupled to factor viii or functional variant thereof either through a linking group or as a fusion protein..
Neurotoxins exhibiting shortened biological activity
The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides.
Merz Pharma Gmbh & Co. Kgaa
Lipidomic biomarkers for identification of high-risk coronary artery disease patients
The present invention inter alia provides a method, and use thereof, of predicting severe cvd complications such as ami or cvd death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these cvd complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating cvd complications.
Zora Biosciences Oy
Use and treatment of di-amino acid repeat-containing proteins associated with als
Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (als) or frontotemporal dementia (ftd). antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein..
University Of Florida Research Foundation, Inc.
Plasmonic substrate for multiplex assessment of type 1 diabetes
Disclosed are methods and materials providing fluorescence detection of autoantibodies present in individuals who have developed or are at risk for type 1 diabetes. Provided is a plasmonic chip capable of fluorescence-enhancement of >100-fold.
The Board Of Trustees Of The Leland Stanford Junior University
Polymer backbone element tags
Element tags based on novel metal-polymer conjugates are provided for elemental analysis of analytes, including icp-ms. A polymer backbone is functionalized to irreversibly bind metals that are selected prior to use by the user.
Fluidigm Canada Inc.
Method for pretreating specimen and assaying biological substance
This invention relates to an assay device and a method for pretreating a specimen containing a biologically-relevant substance and then assaying the biologically-relevant substance. Biologically-relevant substances used in the assay method include microorganisms, cells, viruses, nucleic acids, polysaccharides, proteins (including antigens, antibodies, chromoproteins, and enzymes), peptides, nucleic acids, and small molecules.
Universal Bio Research Co., Ltd.
The invention relates to a method for detection of at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19, and/or soluble fragments thereof, in a sample, comprising the steps of contacting said sample with a solid phase having immobilized thereon a first antibody having specificity for cytokeratin 8, a second antibody having specificity for cytokeratin 18 and, optionally,a third antibody having specificity for a first epitope of cytokeratin 19; allowing cytokeratin and/or soluble fragments thereof in said sample to bind to said first, second and optionally third antibodies thereby forming complexes; contacting said complexes with a first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and optionally a second labelled antibody having specificity for a second epitope of cytokeratin 19; allowing said first and second labelled antibodies to bind to said complexes; and detecting said first labelled antibody and said second labelled antibody bound to said complexes. The invention further relates to a method for quantitative determination of soluble fragments of at least two of cytokeratin 8, 18 and 19 in a sample and to a kit-of-parts for performing the method according to the invention..
Idl Biotech Ab
Method for electronic biological sample analysis
A biological sample analysis device includes a casing that encloses a biological sample delivery system hydraulically coupled to a sensor, wherein the sensor includes a plurality of graphene transistors and each transistor covalently bonds with a biomarker causing the electrical properties of the transistor to measurably change when the biomarker is exposed to corresponding antibodies within an infected biological sample.. .
Nanomedical Diagnostics, Inc.
Method for manufacturing an immune cell-containing composition, and a cancer-treating composition
To provide a method in which mononuclear cells are differentiated into a good balance of nk cells, nkt cells, and t cells, and said cells are made to proliferate. The present invention provides a method for manufacturing an immune cell-containing composition, said method including the following steps: a first step in which mononuclear cells are cultured in a medium containing anti-cd16 monoclonal antibodies and either il-2 and/or il-15; and a second step, after the first step, in which culturing is performed under conditions that make the mononuclear cells preferentially differentiate into cytotoxic t cells.
Anti-factor b antibodies and their uses
The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (cnv) and age-related macular degeneration (amd), by administration of factor b antagonists.. .
Monoclonal antibodies against antithrombin b
This patent document relates to antibodies, antigen-binding antibody fragments (fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (atβh). These atβh binding proteins can block the anti-coagulant activity of atβ to induce coagulation.
Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to fucosyl-gm1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.
Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Production of proteins in glutamine-free cell culture media
The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture..
Llt-1 antibodies with new functional properties
The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (llt1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which llt1- and cd161-expressing cells play a role in disease pathogenesis..
Centre National De La Recherche Scientifique
Antibodies against human nkg2d and uses thereof
The present invention provides isolated anti-human nkg2d monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient.
Novo Nordisk A/s
Humanized anti-hla-dr antibodies
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the b7-h7 counter-receptor, h7cr, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.. .
The Johns Hopkins University
Antigen binding constructs to cd8
Antigen binding constructs that bind to cd8, for example antibodies, including antibody fragments (such as scfv, minibodies, and cys-diabodies) that bind to cd8, are described herein. Methods of use are described herein..
Human antibodies to nav1.7
The present invention provides antibodies that bind to the human voltage gated sodium channel designated nav 1.7 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human nav 1.7 (hnav 1.7).
Regeneron Pharmaceuticals, Inc.
Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
Embodiments of the invention provide high affinity recombinant epcam-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided.
The Board Of Regents Of The University Of Texas System
Methods for producing antibodies
The present invention describes a method for producing an antibody in pichia pastoris, such as by fed-batch fermentation. The method includes a respiratory quotient control for monitoring the ethanol profile and to improve the quality of the antibody by, for example, eliminating clipping of the heavy chain.
Bristol-myers Squibb Company
Methods of producing antibodies in yeast
The present invention describes a method for producing an antibody in pichia pastoris, such as by fed-batch fermentation. The method includes the addition of about 2.0-5.0 g/l of hydroxyurea during the fermentation process to sustain a constant cell density and enhance the whole broth titer of the antibody.
Bristol-myers Squibb Company
Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
The present disclosure relates to an isolated human monoclonal antibody or antibody fragment that has a high potency for neutralizing the bioactivity of gm-csf comprising the heavy chain cdr sequences of seq id nos: 1, 2 and 3 and the light chain cdr sequences of seq id nos: 7, 8 and 9, or functional variants thereof. The disclosure also relates to methods and uses of the antibody or antibody fragment for suppressing an immune response, heating inflammation, pain, cancer, and bone or cartilage loss..
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
Disclosed herein are human monoclonal antibodies that specifically bind both igf-i and igf-ii with picomolar affinity and potently inhibit the igf-ir signal transduction function. These antibodies are active in both an igg and a scfv format.
The United States Of America, As Represented By The Secretary, Department Of Health And Human
Connective tissue growth factor antibodies
The present invention relates to antibodies that bind to ctgf. The antibodies are particularly directed to regions of ctgf involved in biological activities associated with fibrosis.
Antibodies against amyloid-beta peptide
antibodies that bind human β-amyloid peptide, methods of treating diseases or disorders characterised by elevated β-amyloid levels or β-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.. .
Glaxo Group Limited
Human antibodies to grem1
The present invention provides antibodies that bind to human gremlin-1 (grem1), and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to grem1.
Regeneron Pharmaceuticals, Inc.
Compositions and methods for treating angiogenesis-related disorders
Provided herein are anti-angiogenic monoclonal antibodies and antigen-binding antibody fragments that selectively and specifically bind to an epitope in both fibronectin and either fibrinogen or fibrin fragment e, compositions containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.. .
Fee Therapeutics Llc
Anti-tau antibodies and methods of use
The present invention relates to anti-tau antibodies, such as antibodies that bind to a phosphorylated epitope on human tau protein with high specificity and/or affinity, and methods of using the same.. .
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions.
Celldex Therapeutics Inc.
Flavivirus neutralizing antibodies and methods of use thereof
The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mab11 which recognizes west nile virus e protein and is cross-reactive with members of the flavivirus family, including denge virus.
Dana-farber Cancer Institute, Inc.
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
Described are binding molecules such as human monoclonal antibodies that bind to influenza virus h5n1 and have neutralizing activity against influenza virus h5n1. Also described are polynucleotides encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies.
Crucell Holland B.v.
Methods and compositions related to intracellular neutralization by igg
Disclosed are compositions, antibodies, and methods for binding intracellular antigens.. .
University Of Maryland
Biological therapeutics for infection-relating disorders or conditions
The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies.
Identification of antibodies specific for lyssaviruses and methods of their use
Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as rabv, mokv and wcbv) and/or specifically bind recombinant glycoprotein from different lyssaviruses..
The Government Of The United States Of America As Represented By The Secretary Of The Department Of
Haemophilus influenzae type b
Polypeptides comprising various amino acid sequences derived from haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis.
J. Craig Venter Institute, Inc.
An epitope and its use
An isolated protein containing a common epitope recognized by umbilical blood antibodies specific against enterobacteria, occurring in an extract of bacterial outer membrane proteins, and fragments thereof containing said common epitope, which can be used in medicine and pharmaceutics, particularly in the production of vaccines and diagnostic tests as well as affinity materials.. .
Wroclawskie Centrum Badan Eit + Sp. Z O.o.
Purification platform for bispecific antibodies
High resolution protein a chromatography employing a chaotropic agent and ph gradient or ph step elution buffer results in improved peak resolution between closely related molecular species. Bispecific antibodies containing a protein a-binding-ablating substitution ch3 domain paired with a protein a-binding ch3 domain are separated with high peak resolution from monospecific antibodies containing a protein a-binding-ablating substituted ch3 domain paired with the protein a-binding-ablating substituted ch3 domain and monospecific antibodies containing a protein a-binding ch3 domain paired with the protein a-binding ch3 domain.
Regeneron Pharmaceuticals, Inc.
Methods for purifying antibodies
A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.. .
Glaxosmithkline Intellectual Property (no.2) Limited
Hydrophobic interaction protein chromatography under no-salt conditions
Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.. .
Biogen Ma Inc.
Targeted polymeric inflammation-resolving nanoparticles
Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or nmr contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging.
The Trustees Of Columbia University
Solid phase tgase-mediated conjugation of antibodies
Some embodiments described herein relate to solid-support based processess for the functionalization of immunoglobulins through the use of transglutaminase. Also provided are solid support compositions with bound antibody.
Compositions comprising anti-cd38 antibodies and carfilzomib
Disclosed herein are compositions and kits which comprise anti-cd38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits..
The Regents Of The University Of California
Antigen presenting cell targeted cancer vaccines
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
Baylor Research Institute